Overcoming multidrug resistance using liposomal epirubicin and antisense oligonucleotides targeting pump and nonpump resistances in vitro and in vivo

Biomedicine and Pharmacotherapy

Volumn 67, Issue 4, 2013, Pages 261-267

  Lo, Yu Li ^a   Liu, Yu ^a   Tsai, Jui Chen ^b  

^a NATIONAL UNIVERSITY OF TAINAN   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Antisense oligonucleotides; ASOs; CT26; Epi; Epirubicin; MDR; MRPs; MTT; Multidrug resistance; P gp; PEGylated

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; EPIRUBICIN; MACROGOL; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; PROTEIN BCL 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE; CELL CYCLE G1 PHASE; COLON ADENOCARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; IN VITRO STUDY; IN VIVO STUDY; MALE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; RAT;

ADENOCARCINOMA; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; AREA UNDER CURVE; COLONIC NEOPLASMS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; EPIRUBICIN; HALF-LIFE; LIPOSOMES; MALE; MICE; MICE, INBRED BALB C; MOLECULAR TARGETED THERAPY; OLIGONUCLEOTIDES, ANTISENSE; POLYETHYLENE GLYCOLS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84876927680     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2012.12.002     Document Type: Article

References (22)

1. Wacheck V., Zangemeister-Wittke U. Antisense molecules for targeted cancer therapy. Crit Rev Oncol Hematol 2006, 59:65-73.
2. Watts J.K., Corey D.R. Silencing disease genes in the laboratory and the clinic. J Pathol 2012, 226:365-379.
3. Lage H. An overview of cancer multidrug resistance: a still unsolved problem. Cell Mol Life Sci 2008, 65:3145-3167.
4. Wang X., Wang C., Qin Y.W., et al. Simultaneous suppression of multidrug resistance and antiapoptotic cellular defense induces apoptosis in chemoresistant human acute myeloid leukemia cells. Leuk Res 2007, 31:989-994.
5. Lo Y.L., Ho C.T., Tsai F.L. Inhibit multidrug resistance and induce apoptosis by using glycocholic acid and epirubicin. Eur J Pharm Sci 2008, 35:52-67.
6. Minko T., Dharap S.S., Pakunlu R.I., et al. Molecular targeting of drug delivery systems to cancer. Curr Drug Targets 2004, 5:389-406.
7. Pakunlu R.I., Wang Y., Saad M., et al. In vitro and in vivo intracellular liposomal delivery of antisense oligonucleotides and anticancer drug. J Control Release 2006, 114:153-162.
8. Yamanaka K., Rocchi P., Miyake H., et al. Induction of apoptosis and enhancement of chemosensitivity in human prostate cancer LNCaP cells using bispecific antisense oligonucleotide targeting Bcl-2 and Bcl-xL genes. BJU Int 2006, 97:1300-1308.
9. Yamanaka K., Rocchi P., Miyake H., et al. A novel antisense oligonucleotide inhibiting several antiapoptotic Bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells. Mol Cancer Ther 2005, 4:1689-1698.
10. Perouzel E., Jorgensen M.R., Keller M., et al. Synthesis and formulation of neoglycolipids for the functionalization of liposomes and lipoplexes. Bioconjug Chem 2003, 14:884-898.
11. Li S.D., Huang L. Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells. Mol Pharm 2006, 3:579-588.
12. Plosker G.L., Faulds D. Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy. Drugs 1993, 45:788-856.
13. Lo Y.L., Hsu C.Y., Lin H.R. pH-and thermo-sensitive pluronic/poly(acrylic acid) in situ hydrogels for sustained release of an anticancer drug. J Drug Target 2012, [in press]. 10.3109/1061186X.2012.725406.
14. Sullivan J.M., Yau E.H., Taggart R.T., et al. Relieving bottlenecks in RNA drug discovery for retinal diseases. Adv Exp Med Biol 2012, 723:145-153.
15. Davids M.S., Letai A. Targeting the B-cell lymphoma/leukemia 2 family in cancer. J Clin Oncol 2012, 30:3127-3135.
16. Liu D., Hu Q., Song Y.K. Liposome clearance from blood: different animal species have different mechanisms. Biochim Biophys Acta 1995, 1240:277-284.
17. Marbeuf-Gueye C., Salerno M., Quidu P., et al. Inhibition of the P-glycoprotein- and multidrug resistance protein-mediated efflux of anthracyclines and calceinacetoxymethyl ester by PAK-104P. Eur J Pharmacol 2000, 391:207-216.
18. Buchholz T.A., Davis D.W., McConkey D.J., et al. Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy. Cancer J 2003, 9:33-41.
19. Harada T., Ogura S., Yamazaki K., et al. Predictive value of expression of P53, Bcl-2 and lung resistance-related protein for response to chemotherapy in non-small cell lung cancers. Cancer Sci 2003, 94:394-399.
20. Miao Z.H., Tang T., Zhang Y.X., et al. Cytotoxicity, apoptosis induction and downregulation of MDR-1 expression by the anti-topoisomerase II agent, salvicine, in multidrug-resistant tumor cells. Int J Cancer 2003, 106:108-115.
21. Haley B., Frenkel E. Nanoparticles for drug delivery in cancer treatment. Urol Oncol 2008, 26:57-64.
22. Zhang W., Shi Y., Chen Y., et al. The potential of Pluronic polymeric micelles encapsulated with paclitaxel for the treatment of melanoma using subcutaneous and pulmonary metastatic mice models. Biomaterials 2011, 32:5934-5944.